Antje Sucker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Antje Sucker has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
- Dirk Schadendorf
Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
73 shared publications - Klaus Georg Griewank
Department of Dermatology, Venereology and Allergology, University Hospital Essen , Essen
69 shared publications - Eva Hadaschik
Department of Dermatology, Venereology and Allergology, University Hospital Essen, Essen, Germany
65 shared publications - Anne Zaremba
University Hospital Essen 1 Essen
63 shared publications - Annette Paschen
Department of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
62 shared publications - Alexander Roesch
Department of Dermatology, University Hospital Essen, 45147 Essen, Germany
58 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
A functional TIGIT-associated transcriptional program identifies circulating tumor-reactive CD8⁺ T cells in melanoma patients
Accessing tumor-reactive CD8⁺ T cells in patient blood is essential for non-invasive monitoring of systemic T cell responses and guiding personalized therapies. However, precise functional, molecular, and phenotypic characterization of these cells remains challenging. Here, we identify TIGIT as a functionally validated surrogate marker of tumor-reactive CD8⁺ T cells and define its associated transcriptional program to characterize circulating tumor-reactive CD8⁺ T cells in melanoma patients. We demonstrate that blood TIGIT⁺ CD8⁺ T cells mount robust cytotoxic responses against autologous tumor cells across multiple melanoma patient models, irrespective of PD-1 co-expression. At the clonotype level, TIGIT broadened detection of the circulating tumor-reactive repertoire beyond PD-1 while retaining high specificity. Moreover, circulating TIGIT⁺ CD8⁺ T cell population was closely associated with the intratumoral T cell repertoire and exhibited hallmarks of antigen experience, including effector memory differentiation, a hypomethylated DNA landscape, and increased clonal expansion. Longitudinal profiling of blood samples from melanoma patients undergoing immune checkpoint inhibition revealed an increased frequency of TIGIT⁺ CD8⁺ T cells in clinical responders. Finally, leveraging paired single-cell transcriptomic and TCR data from patient models with identified tumor-reactive clones, we show that the TIGIT-associated transcriptional program enables robust detection of circulating tumor-reactive CD8⁺ T cells. Collectively, our data establish TIGIT⁺ CD8⁺ T cells as a potent reservoir of tumor-reactive T cells in peripheral blood and provide a blood-based framework for accelerating TCR discovery and advancing adoptive cell therapy.
- 17 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
Open AccessA functional TIGIT-associated transcriptional program identifies circulating tumor-reactive CD8⁺ T cells in melanoma patients
Accessing tumor-reactive CD8⁺ T cells in patient blood is essential for non-invasive monitoring of systemic T cell responses and guiding personalized therapies. However, precise functional, molecular, and phenotypic characterization of these cells remains challenging. Here, we identify TIGIT as a functionally validated surrogate marker of tumor-reactive CD8⁺ T cells and define its associated transcriptional program to characterize circulating tumor-reactive CD8⁺ T cells in melanoma patients. We demonstrate that blood TIGIT⁺ CD8⁺ T cells mount robust cytotoxic responses against autologous tumor cells across multiple melanoma patient models, irrespective of PD-1 co-expression. At the clonotype level, TIGIT broadened detection of the circulating tumor-reactive repertoire beyond PD-1 while retaining high specificity. Moreover, circulating TIGIT⁺ CD8⁺ T cell population was closely associated with the intratumoral T cell repertoire and exhibited hallmarks of antigen experience, including effector memory differentiation, a hypomethylated DNA landscape, and increased clonal expansion. Longitudinal profiling of blood samples from melanoma patients undergoing immune checkpoint inhibition revealed an increased frequency of TIGIT⁺ CD8⁺ T cells in clinical responders. Finally, leveraging paired single-cell transcriptomic and TCR data from patient models with identified tumor-reactive clones, we show that the TIGIT-associated transcriptional program enables robust detection of circulating tumor-reactive CD8⁺ T cells. Collectively, our data establish TIGIT⁺ CD8⁺ T cells as a potent reservoir of tumor-reactive T cells in peripheral blood and provide a blood-based framework for accelerating TCR discovery and advancing adoptive cell therapy.
- Open Access
- 30 June 2026
- Published by Elsevier in EJC Skin Cancer
- Vol. 4
Single-center clinico-genomic analysis of KIT mutated melanomas and clinical outcomes with tyrosine kinase inhibitor treatment
- 30 June 2026
- Published by Elsevier in EJC Skin Cancer
- Vol. 4
Open AccessSingle-center clinico-genomic analysis of KIT mutated melanomas and clinical outcomes with tyrosine kinase inhibitor treatment
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
No chromosomal alterations in the MHC region of HLA-II-loss JAK1/2 mutant melanoma cells
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
No chromosomal alterations in the MHC region of HLA-II-loss JAK1/2 mutant melanoma cells
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
HLA-II expression in longitudinal melanoma samples
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
HLA-II expression in longitudinal melanoma samples
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
Homogeneous HLA-I and PD-L1 expression in consecutive melanoma samples from patient Ma-Mel-61
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
Homogeneous HLA-I and PD-L1 expression in consecutive melanoma samples from patient Ma-Mel-61
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
CD4 T-cell sensitivity of constHLA-II melanoma cells
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
CD4 T-cell sensitivity of constHLA-II melanoma cells
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
JAK inhibition downregulates HLA-II but not HLA-I or PD-L1 expression in melanoma cells
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
JAK inhibition downregulates HLA-II but not HLA-I or PD-L1 expression in melanoma cells
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
ConstHLA-II melanoma cells lack endogenous interferon expression
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
ConstHLA-II melanoma cells lack endogenous interferon expression
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
HLA-II APM transcript levels in melanoma biopsies from ICB-treated patients
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
HLA-II APM transcript levels in melanoma biopsies from ICB-treated patients
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
Purpose:Recent studies have demonstrated HLA class II (HLA-II)–dependent killing of melanoma cells by cytotoxic CD4 T cells. We investigated evolution of HLA-II–loss tumors that escape cytotoxic CD4 T-cell activity and contribute to immunotherapy resistance.Experimental Design:Melanoma cells from longitudinal metastases were studied for constitutive and IFN-inducible HLA-II expression, sensitivity towards autologous CD4 T cells, and immune evasion by HLA-II loss. Clinical significance of HLA-II–low tumors was determined by analysis of transcriptomic data sets from patients with immune checkpoint blockade (ICB).Results:Analysis of longitudinal samples revealed strong intermetastatic heterogeneity in melanoma cell–intrinsic HLA-II expression and subclonal HLA-II loss. Tumor cells from early lesions either constitutively expressed HLA-II, sensitizing to cytotoxic CD4 T cells, or induced HLA-II and gained CD4 T-cell sensitivity in the presence of IFNγ. In contrast, late outgrowing subclones displayed a stable CD4 T-cell–resistant HLA-II–loss phenotype. These cells lacked not only constitutive but also IFNγ-inducible HLA-II due to JAK1/2-STAT1 pathway inactivation. Coevolution of JAK1/2 deficiency and HLA-II loss established melanoma cross-resistance to IFNγ and CD4 T cells, as detected in distinct stage IV metastases. In line with their immune-evasive phenotype, HLA-II–low melanomas showed reduced CD4 T-cell infiltrates and correlated with disease progression under ICB.Conclusions:Our study links melanoma resistance to CD4 T cells, IFNγ, and ICB at the level of HLA-II, highlighting the significance of tumor cell–intrinsic HLA-II antigen presentation in disease control and calling for strategies to overcome its downregulation for improvement of patient outcome.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance
Purpose:Recent studies have demonstrated HLA class II (HLA-II)–dependent killing of melanoma cells by cytotoxic CD4 T cells. We investigated evolution of HLA-II–loss tumors that escape cytotoxic CD4 T-cell activity and contribute to immunotherapy resistance.Experimental Design:Melanoma cells from longitudinal metastases were studied for constitutive and IFN-inducible HLA-II expression, sensitivity towards autologous CD4 T cells, and immune evasion by HLA-II loss. Clinical significance of HLA-II–low tumors was determined by analysis of transcriptomic data sets from patients with immune checkpoint blockade (ICB).Results:Analysis of longitudinal samples revealed strong intermetastatic heterogeneity in melanoma cell–intrinsic HLA-II expression and subclonal HLA-II loss. Tumor cells from early lesions either constitutively expressed HLA-II, sensitizing to cytotoxic CD4 T cells, or induced HLA-II and gained CD4 T-cell sensitivity in the presence of IFNγ. In contrast, late outgrowing subclones displayed a stable CD4 T-cell–resistant HLA-II–loss phenotype. These cells lacked not only constitutive but also IFNγ-inducible HLA-II due to JAK1/2-STAT1 pathway inactivation. Coevolution of JAK1/2 deficiency and HLA-II loss established melanoma cross-resistance to IFNγ and CD4 T cells, as detected in distinct stage IV metastases. In line with their immune-evasive phenotype, HLA-II–low melanomas showed reduced CD4 T-cell infiltrates and correlated with disease progression under ICB.Conclusions:Our study links melanoma resistance to CD4 T cells, IFNγ, and ICB at the level of HLA-II, highlighting the significance of tumor cell–intrinsic HLA-II antigen presentation in disease control and calling for strategies to overcome its downregulation for improvement of patient outcome.